Edition:
India

Otonomy Inc (OTIC.OQ)

OTIC.OQ on NASDAQ Stock Exchange Global Select Market

2.58USD
18 Apr 2019
Change (% chg)

$0.05 (+1.98%)
Prev Close
$2.53
Open
$2.52
Day's High
$2.60
Day's Low
$2.44
Volume
11,274
Avg. Vol
29,607
52-wk High
$4.85
52-wk Low
$1.50

Latest Key Developments (Source: Significant Developments)

Otonomy Inc Says Entered Into Loan And Security Agreement
Thursday, 3 Jan 2019 

Jan 3 (Reuters) - Otonomy Inc ::OTONOMY INC SAYS ON DEC 31, ENTERED INTO A LOAN AND SECURITY AGREEMENT - SEC FILING.OTONOMY INC - LOAN AGREEMENT PROVIDES FOR A $15.0 MILLION SECURED TERM LOAN CREDIT FACILITY.  Full Article

Otonomy Expects 2020 Operating Expenses To Be Lower Than 2019
Thursday, 3 Jan 2019 

Jan 3 (Reuters) - Otonomy Inc ::OTONOMY PROVIDES CORPORATE AND PRODUCT PIPELINE UPDATE.CURRENT CAPITAL FUNDS OPERATIONS INTO 2021.THREE PROGRAMS WITH CLINICAL TRIAL RESULTS IN 2020 INCLUDING OTIVIDEX PHASE 3 TRIAL IN MÉNIÈRE'S DISEASE.OTONOMY - EXPECTS TO HAVE CLINICAL TRIAL RESULTS FOR THREE PROGRAMS IN 2020.FINISHED 2018 WITH ABOUT $97 MILLION IN CASH, CASH EQUIVALENTS AND SHORT TERM INVESTMENTS.OTONOMY REAFFIRMS ITS EXPECTATIONS THAT GAAP OPERATING EXPENSES WILL BE IN RANGE OF $52-$57 MILLION IN 2018.OTONOMY REAFFIRMS ITS EXPECTATIONS THAT NON-GAAP OPERATING EXPENSES WILL BE AT LOWER END OF ITS $40-$45 MILLION GUIDANCE IN 2018.IN 2020, EXPECTS THAT OPERATING. EXPENSES WILL BE LOWER THAN 2019 AS MULTIPLE CLINICAL TRIALS ARE COMPLETED.OTONOMY - FOR 2019, CO EXPECTS THAT GAAP OPERATING EXPENSES WILL BE IN RANGE OF $55-$60 MILLION, NON-GAAP OPERATING EXPENSES WILL BE IN RANGE OF $45-$50 MILLION.  Full Article

Otonomy Qtrly Loss Per Share $0.41
Tuesday, 6 Nov 2018 

Nov 5 (Reuters) - Otonomy Inc ::OTONOMY REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.OTONOMY INC - REAFFIRMS ITS EXPECTATIONS THAT GAAP OPERATING EXPENSES FOR 2018 WILL BE IN RANGE OF $52-$57 MILLION.OTONOMY INC - QTRLY LOSS PER SHARE $0.41.  Full Article

Otonomy Inc Files For Mixed Shelf Offering Of Up To $150 Mln
Tuesday, 11 Sep 2018 

Sept 10 (Reuters) - Otonomy Inc ::OTONOMY INC FILES FOR MIXED SHELF OFFERING OF UP TO $150 MILLION – SEC FILING.  Full Article

Otonomy Qtrly Loss Per Share $‍0.62​
Friday, 9 Mar 2018 

March 8 (Reuters) - Otonomy Inc ::OTONOMY REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.QTRLY LOSS PER SHARE $‍0.62​.‍REAFFIRMS ITS EXPECTATIONS THAT GAAP OPERATING EXPENSES FOR 2018 WILL BE IN RANGE OF $52-$57 MILLION​.  Full Article

Otonomy Announces FDA Approval Of Otiprio For Acute Otitis Externa
Friday, 2 Mar 2018 

March 2 (Reuters) - Otonomy Inc ::OTONOMY ANNOUNCES FDA APPROVAL OF OTIPRIO(R) FOR ACUTE OTITIS EXTERNA.FDA APPROVED OTIPRIO FOR TREATING ACUTE OTITIS EXTERNA IN PATIENTS 6 MONTHS & OLDER DUE TO PSEUDOMONAS AERUGINOSA & STAPHYLOCOCCUS AUREUS.  Full Article

Otonomy Sees 2017 Non-Gaap Expenses Totaling $73-$78 Million
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Otonomy Inc ::OTONOMY INC - EXPECTS GAAP OPERATING EXPENSES FOR 2017 TO TOTAL IN RANGE OF $95-$100 MILLION.OTONOMY PROVIDES CORPORATE AND PRODUCT PIPELINE UPDATE.OTONOMY INC - SEES 2017 NON-GAAP EXPENSES TOTALING $73-$78 MILLION.OTONOMY - CASH BALANCE INCLUDING CASH, CASH EQUIVALENTS, & SHORT-TERM INVESTMENTS TOTALED $120 MILLION AT END OF 2017.OTONOMY SAYS CASH BALANCE EXPECTED TO FUND COMPLETION OF CLINICAL DEVELOPMENT REQUIRED FOR U.S. REGISTRATION OF OTIVIDEX IN MÉNIÈRE'S DISEASE.  Full Article

Otonomy Inc Immediately Discontinuing Commercial Support For Otiprio
Tuesday, 28 Nov 2017 

Nov 27 (Reuters) - Otonomy Inc ::OTONOMY INC - ‍ IS IMMEDIATELY DISCONTINUING COMMERCIAL SUPPORT FOR OTIPRIO WHICH IS EXPECTED TO SIGNIFICANTLY REDUCE FUTURE OPERATING EXPENSES​.OTONOMY INC - ‍ DISCONTINUING COMMERCIAL SUPPORT FOR OTIPRIO EXPECTED TO RESULT IN ESTIMATED CASH SAVINGS OF MORE THAN $20 MILLION IN 2018​.OTONOMY INC - ‍ DISCUSSIONS ARE UNDERWAY TO DIVEST OTIPRIO​.OTONOMY INC - ‍IS ELIMINATING EMPLOYMENT POSITIONS AND CEASING PROGRAMS RELATED TO COMMERCIALIZATION AND MARKET SUPPORT OF OTIPRIO​.OTONOMY INC - ‍ELIMINATING COMMERCIAL PERSONNEL REDUCES OTONOMY'S HEADCOUNT TO APPROXIMATELY 50​.OTONOMY INC - ‍OTONOMY IS NOT PREPARED TO PROVIDE OPERATING EXPENSE GUIDANCE FOR 2018 AT THIS TIME​.OTONOMY - ‍INCLUDING SEVERANCE PAYMENTS, COMMERCIAL PROGRAM WIND-DOWN COSTS, TOTAL GAAP OPERATING EXPENSES FOR 2017 EXPECTED TO BE ABOUT $95-$100 MILLION​.OTONOMY INC - NON-GAAP EXPENSES FOR 2017 ARE EXPECTED TO TOTAL IN RANGE OF $73 MILLION-$78 MILLION​.OTONOMY INC - ‍EXPECTS ITS CASH BALANCE INCLUDING CASH, CASH EQUIVALENTS, AND SHORT-TERM INVESTMENTS TO TOTAL $118 MILLION-$123 MILLION AT END OF 2017​.OTONOMY INC - ‍ INTENDS TO COMPLETE CLINICAL DEVELOPMENT TO SUPPORT REGISTRATION OF OTIVIDEX IN UNITED STATES FOR PATIENTS WITH MÉNIÈRE'S DISEASE.  Full Article

Otonomy reports third quarter loss of $0.69 per share
Thursday, 9 Nov 2017 

Nov 8 (Reuters) - Otonomy Inc :Otonomy reports third quarter 2017 financial results and provides corporate update.Cash, cash equivalents, and short-term investments totaled $134.3 million as of Sept 30, 2017, compared to $196.4 million as of Dec 31, 2016​.Qtrly net loss per share , basic and diluted $0.69‍​.  Full Article

Otonomy reports positive results from averts-2 phase 3 trial of otividex™ in patients with ménière's disease
Thursday, 9 Nov 2017 

Nov 8 (Reuters) - Otonomy Inc :Otonomy reports positive results from Averts-2 Phase 3 trial of Otividex™ in patients with Ménière's disease.Otonomy reports positive results from Averts-2 Phase 3 trial of Otividex™ in patients with Ménière's disease.Otonomy Inc - ‍achieved primary endpoint in study​.Otonomy Inc - ‍company plans to meet with FDA to discuss results of study and clinical requirements for registration​.Otonomy Inc - ‍otividex was generally well-tolerated with no drug-related serious adverse events observed​.  Full Article